Eli Lilly's monoclonal antibody Taltz has received approval by Health Canada for the treatment of adults with nonradiographic axial spondyloarthritis.
Three things to know:
1. Axial spondyloarthritis primarily affects the sacroiliac joints and the spine, resulting in chronic inflammatory back pain and fatigue.
2. The drug is cleared to treat patients who show signs of inflammation but have not responded to conventional therapy.
3. This is the fourth indication for Taltz. Health Canada has also cleared the drug for plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.